Skripsi
EFEKTIVITAS PENAMBAHAN RESVERATROL TERHADAP PERBAIKAN DISFUNGSI ENDOTHEL DAN KENDALI METABOLIK PADA PASIEN DM TIPE 2 DI RS DR. MOHAMMAD HOESIN PALEMBANG
Effectiveness of Resveratrol Addition in Endothelial Dysfunction and Metabolic Control in Type 2 DM Patients at dr. Mohammad Hoesin Hospital Palembang Rita Sriwulandari*, Yulianto Kusnadi*, Taufik Indrajaya**, Legiran*** *Endocrine Metabolic Diabetes Division, ** Cardiology Division Internal Medicine Section/ Faculty of Medicine Sriwijaya University Palembang *** Anatomy Section Faculty of Medicine Sriwijaya University Palembang Abstract Background: Chronic hyperglycemia causes high intra-endothelial cell glucose concentrations, leading to oxidative stress and formation of reactive oxygen species (ROS). ROS are the main factors in endothelial dysfunction, characterised by decreased bioavailability of Nitric Oxide (NO). Resveratrol has been studied to have anti-inflammatory and antioxidant effects and plays a role in mitochondrial biogenesis, autophagy, re-endothelialisation, and changes in endothelial cell morphology so it is thought to play a role in preventing cardiovascular disease (CVD). This study aims to see the effectiveness of Resveratrol in improving endothelial dysfunction and metabolic control in Type 2 DM patients at dr. Mohammad Hoesin Hospital Palembang Method: Forty-three Type 2 DM patients aged 57 (36-72) years, 60.5% female, with endothelial dysfunction were enrolled in a randomised, double-blind, placebo-controlled trial to assess the effects of 3 months of 50 mg of Resveratrol supplementation on improving endothelial dysfunction and metabolic control. Endothelial dysfunction was measured by flow-mediated dilation (FMD) and serum endothelial Nitric Oxide Synthase (eNOS) levels, while metabolic control was measured by HbA1C, FPG, PPG, HDL, LDL, total cholesterol, and triglyceride. Results: Compared with placebo, there was a significant increase in FMD in the Resveratrol group by 3.5% (with a range of -1.80 to 15.20, p = 0.034). The multivariate linear regression model for FMD produced B value 2,540 and 95% CI for B 0,494 - 4,586 and r² value of 0.248, indicating that approximately 24.8% of the variation in the increase in FMD can be explained by the variables in the model, namely treatment with Resveratrol and delta HDL, while 75.2% is influenced by other factors. The levels of eNOS, HbA1C, FBG, PBG, HDL, LDL, Total Cholesterol and Triglycerides did not change significantly, indicating that the increase in FMD was not associated with traditional cardiovascular risk factors. Conclusion: Resveratrol effectively improves endothelial dysfunction as measured by increased FMD, but is ineffective on eNOS levels and metabolic control in Type 2 DM patients dr. Mohammad Hoesin Hospital Palembang Keywords: Resveratrol, Endothelial dysfunction, FMD, eNOS, Metabolic Control